 Clinical Oncology News | New TKI Ponatinib Effective in Resistant CML Clinical Oncology News This agent provides another option for patients who become resistant to standard TKIs, where the only other options include interferon or allogeneic bone marrow transplantation. The side effects of this new agent are similar to the other TKIs ... |
